Level C· Early human research exploring benefitsRetrospective StudyPubMed

Is nanofat the long-awaited treatment for hypertensive ischemic leg ulcers?

Moris V., Terrasa M., Goubeau E., See LA., Guillier D., Zwetyenga N.

Retrospective Study with a reported sample of 23 on Chronic Wound, Scar, published in Wounds (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Wounds (2025)
Country
United States
Reported sample size
23
Source database
PubMed
PMID
40053428
DOI
10.25270/wnds/24072
Citations
1

Abstract (original English)

Martorell hypertensive ischemic leg ulcer (HYTILU) is a chronic, hard-to-heal wound linked to hypertension. This study explores nanofat grafting as a regenerative alternative to traditional skin grafting for improved healing and patient outcomes. To explore the efficacy of nanofat grafting in the management of HYTILU and compare it with skin grafting. This was a retrospective single-center pilot study involving 23 patients with HYTILU treated with adipose-derived stromal cells (adipose-derived stromal cells/nanofat). The primary outcomes were ulcer healing rate, pain reduction, and improvements in quality of life, as measured by SCAR-Q (a scar quality of life questionnaire) and the Vancouver Scar Scale, over a period of 6 months posttreatment. This study revealed a significant decrease in ulcer size from an initial mean of 39.69 cm² to complete healing, with an average healing time of 4.65 months. The mean visual analog scale pain scores significantly decreased from an initial score of 5.87 to 0.39 at 3 months postinjection (P < .0001). Quality of life was significantly improved after treatment, as underscored by higher SCAR-Q scores and lower Vancouver scale scores, indicating better scar quality and minimal adverse effects. These study results underscore nanofat grafting as a superior alternative to traditional skin grafting for HYTILU, offering advantages in terms of healing

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansWound HealingMaleFemaleRetrospective StudiesPilot ProjectsLeg UlcerAgedQuality of LifeMiddle Aged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research